Sun Firefights Governance Concerns
Sun has promised to implement certain changes to address corporate governance concerns that have riled investors, including “unwinding” a loan transaction and doing away with a controversial related party arrangement for domestic sales. But will that be enough for markets to "forget" allegations of lapses or "re-rate" the firm any time soon?
You may also be interested in...
Early indications that a whistleblower’s allegations of certain serious irregularities by Sun Pharma may not hold water lifted its shares, though it remains unclear if the issue stands completely closed.
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
Ahead of its Q4 earnings, Sun Pharma has indicated its intent to take additional steps to address investor unease and perceptions around gaps in corporate governance. Investors are expected to keep a close watch on the company's efforts in these areas as well as on management commentary around the US uptake of psoriasis asset Ilumya.